New US Study: Nevisense shows significant positive impact on clinical decision making
New data has been presented in a US publication showing that by including the Nevisense result in clinical decision-making, physicians significantly improved their accuracy in identifying malignant melanoma. The article, titled “Assessment of Clinician Accuracy for Diagnosing Melanoma Based on Electrical Impedance Spectroscopy Score Plus Morphology Versus Lesion Morphology Alone” by Dr Ryan M. Svoboda and others was published online in the Journal of the American Academy of Dermatology (JAAD).
The study was performed as a Reader study in the US, with 164 US physicians reviewing and evaluating clinical images of lesions. The aim of the study was to assess the impact of Nevisense results on the clinician’s diagnostic accuracy and biopsy decisions. Overall 7,380 clinical decisions were made, first based on a lesion’s visual characteristics alone, and secondly based on visual characteristics combined with the Nevisense test result. The addition of Nevisense resulted in 402 fewer missed melanomas and a net decrease of 376 benign biopsies.
“This study shows that integrating the information into the biopsy decision that Nevisense examinations provide led to improved diagnostic accuracy both in terms of sensitivity and specificity, resulting in fewer biopsies of benign lesions and more biopsies of melanomas.” Says Dr Darrell Rigel, Clinical Professor of Dermatology at New York University Medical Center.
Dr Rigel also presented the main findings of the study at the Fall Clinical Congress, held in Las Vegas in October.
“We are very happy with the study results. They show that Nevisense can have a meaningful impact on clinical decisions for US physicians, especially when it comes to helping them more accurately identify malignant melanomas”, says Simon Grant, CEO of SciBase.
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on November 2, 2018.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.